Literature DB >> 8162356

New perspectives in vaccine development: mucosal immunity to infections.

J R McGhee1, H Kiyono.   

Abstract

In this review, we focus on six key areas currently receiving attention in the mucosal immune system. These six areas are of considerable importance for development of vaccines. They are (a) the necessity to understand the unique features of the mucosal immune system; (b) the possibility that the common mucosal immune system may contain distinct compartments; (c) differences in antigen uptake and in types of antigen-presenting cells in mucosal inductive and effector sites; (d) more careful consideration of mucosal memory in vaccine development; (e) recent studies, which show that oral vaccines induce T-helper (Th)-cell subsets that regulate mucosal IgA responses; and (f) the mechanisms whereby mucosal S-IgA and T cells provide mucosal immune protection. An example of the above suffices to illustrate why the selected areas are of importance in vaccine development. Oral immunization preferentially induces type 2 Th (Th2) cell responses that directly correlate with antigen-specific IgA responses in mucosal effector sites. It is likely that activated, antigen-specific Th2 cells that are induced in Peyer's patches are continuously supplied to mucosal effector sites for regulation of IgA responses. These Th2 cells are producing cytokines such as interleukin (IL)-5 and IL-6 and these cytokines may direct antigen-specific surface IgA-positive B cells to become IgA-producing plasma cells. Nevertheless, additional studies will be required to establish that IgA responses to T-cell-dependent antigens depend on Th2 cell-derived help. What are the implications of these studies for current oral vaccines, including novel antigen delivery systems? The most obvious would be that vaccines should be optimized for induction of Th2-cell responses in IgA inductive sites such as the gut-associated lymphoreticular tissues. It is now clear that induction of Th2-type responses in both mucosal inductive and mucosal effector sites are essential for oral vaccines to induce S-IgA responses. However, antigens delivered by live vectors such as Salmonella typhimurium in the murine system and S. typhi in humans must consider T-cell responses induced against a live vector in addition to the inserted recombinant antigen. In this regard, it has been shown that these microorganisms induce cell-mediated immunity responses that largely result from Th1-type cells.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8162356

Source DB:  PubMed          Journal:  Infect Agents Dis        ISSN: 1056-2044


  33 in total

Review 1.  Unsolved mysteries of intestinal M cells.

Authors:  C Nicoletti
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

2.  Natural polyreactive secretory immunoglobulin A autoantibodies as a possible barrier to infection in humans.

Authors:  C P Quan; A Berneman; R Pires; S Avrameas; J P Bouvet
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

Review 3.  From natural polyreactive autoantibodies to à la carte monoreactive antibodies to infectious agents: is it a small world after all?

Authors:  J P Bouvet; G Dighiero
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

4.  Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines.

Authors:  G H Lowell; C Colleton; D Frost; R W Kaminski; M Hughes; J Hatch; C Hooper; J Estep; L Pitt; M Topper; R E Hunt; W Baker; W B Baze
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

Review 5.  A T cell/B cell/epithelial cell internet for mucosal inflammation and immunity.

Authors:  K Fujihashi; M N Kweon; H Kiyono; J L VanCott; F W van Ginkel; M Yamamoto; J R McGhee
Journal:  Springer Semin Immunopathol       Date:  1997

6.  Peyer's patches are required for oral tolerance to proteins.

Authors:  K Fujihashi; T Dohi; P D Rennert; M Yamamoto; T Koga; H Kiyono; J R McGhee
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

Review 7.  Intranasal antibody prophylaxis for protection against viral disease.

Authors:  R Weltzin; T P Monath
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

8.  Development of enhanced antibody response toward dual delivery of nano-adjuvant adsorbed human Enterovirus-71 vaccine encapsulated carrier.

Authors:  Mohamed I Saeed; Abdul Rahman Omar; Mohd Z Hussein; Isam M Elkhidir; Zamberi Sekawi
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

9.  Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus.

Authors:  T Muster; B Ferko; A Klima; M Purtscher; A Trkola; P Schulz; A Grassauer; O G Engelhardt; A García-Sástre; P Palese
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 10.  Improving M cell mediated transport across mucosal barriers: do certain bacteria hold the keys?

Authors:  Angela L Man; Maria Elena Prieto-Garcia; Claudio Nicoletti
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.